Literature DB >> 22270022

Vaccination against infection in patients with multiple sclerosis.

Micha Loebermann1, Alexander Winkelmann, Hans-Peter Hartung, Hartmut Hengel, Emil C Reisinger, Uwe K Zettl.   

Abstract

Bacterial and viral infections have been shown to induce relapses and accelerate the progression of multiple sclerosis (MS). Vaccination to prevent communicable disease in such patients is, therefore, of key importance. Reports of potentially detrimental effects of immunization on the course of MS, however, have prompted patients and physicians to adopt a cautious attitude towards the use of vaccines. The risks associated with a number of vaccines have been investigated in patients with MS. Vaccines against some diseases, such as tetanus and hepatitis B, are not associated with an elevated risk of MS exacerbation, whereas vaccines against other diseases, such as yellow fever, are contraindicated in patients with MS. Many patients with MS receive immunosuppressive or immunomodulatory therapy, which could make them more susceptible to infectious diseases and might also affect their ability to respond to immunization. Here, we review the indications for and possible adverse effects of vaccines in patients with MS, and address issues of vaccination in the context of immunomodulatory therapy for MS.

Entities:  

Mesh:

Year:  2012        PMID: 22270022     DOI: 10.1038/nrneurol.2012.8

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  80 in total

Review 1.  [Current opinion 2004: The relationship between multiple sclerosis and hepatitis B vaccination in adults].

Authors:  O Gout; O Lyon-Caen
Journal:  Rev Neurol (Paris)       Date:  2004-12       Impact factor: 2.607

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

3.  A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis.

Authors:  A E Miller; L A Morgante; L Y Buchwald; S M Nutile; P K Coyle; L B Krupp; C A Doscher; F D Lublin; R L Knobler; F Trantas; L Kelley; C R Smith; N La Rocca; S Lopez
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

4.  Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.

Authors:  I Fomin; D Caspi; V Levy; N Varsano; Y Shalev; D Paran; D Levartovsky; I Litinsky; I Kaufman; I Wigler; E Mendelson; O Elkayam
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

5.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

6.  Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-07-19       Impact factor: 17.586

Review 7.  Environmental factors and their timing in adult-onset multiple sclerosis.

Authors:  Adam E Handel; Gavin Giovannoni; George C Ebers; Sreeram V Ramagopalan
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

8.  Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses.

Authors:  W A Briggs; R J Rozek; S D Migdal; J L Shillis; R G Brackett; F B Brandon; S K Mahajan; F D McDonald
Journal:  Ann Intern Med       Date:  1980-04       Impact factor: 25.391

Review 9.  Tick-borne encephalitis virus - a review of an emerging zoonosis.

Authors:  K L Mansfield; N Johnson; L P Phipps; J R Stephenson; A R Fooks; T Solomon
Journal:  J Gen Virol       Date:  2009-05-06       Impact factor: 3.891

10.  Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives.

Authors:  R N Lipnick; J Karsh; N I Stahl; W C Blackwelder; G Schiffman; J H Klippel
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

View more
  25 in total

Review 1.  [Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Authors:  M Löbermann; B Handorn; A Winkelmann; E C Reisinger; H P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 2.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

4.  Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.

Authors:  Amit Bar-Or; Jonathan C Calkwood; Cathy Chognot; Joanna Evershed; Edward J Fox; Ann Herman; Marianna Manfrini; John McNamara; Derrick S Robertson; Daniela Stokmaier; Jeanette K Wendt; Kevin L Winthrop; Anthony Traboulsee
Journal:  Neurology       Date:  2020-07-29       Impact factor: 9.910

5.  Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.

Authors:  Lahar Mehta; Kimberly Umans; Gulden Ozen; Randy R Robinson; Jacob Elkins
Journal:  Int J MS Care       Date:  2017 May-Jun

Review 6.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 7.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 8.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

9.  Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Authors:  Christoph Metze; Alexander Winkelmann; Micha Loebermann; Michael Hecker; Brunhilde Schweiger; Emil Christian Reisinger; Uwe Klaus Zettl
Journal:  CNS Neurosci Ther       Date:  2018-07-25       Impact factor: 5.243

10.  Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.

Authors:  Valeria Koska; Moritz Förster; Katja Brouzou; Maryam Hatami; Ercan Arat; Ahmet Aytulun; Philipp Albrecht; Orhan Aktas; Patrick Küry; Sven G Meuth; David Kremer
Journal:  Front Neurol       Date:  2021-06-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.